Drug Approval | April 29, 2025
IOL Chemicals and Pharmaceuticals receives approval CDE of NMPA, China for Ibuprofen
This approval authorizes the company to export Ibuprofen to the Chinese markets
This approval authorizes the company to export Ibuprofen to the Chinese markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Subscribe To Our Newsletter & Stay Updated
